| For: | Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol 2014; 20(32): 11400-11405 [PMID: 25170228 DOI: 10.3748/wjg.v20.i32.11400] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i32/11400.htm |
| Number | Citing Articles |
| 1 |
Ai Nakagawa, Masanori Atsukawa, Katsuhiko Iwakiri, Yoshiyuki Narahara, Norio Itokawa, Taeang Arai, Tomomi Okubo, Chisa Kondo, Akihito Tsubota. Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients. World Journal of Gastroenterology 2016; 22(21): 5104-5113 doi: 10.3748/wjg.v22.i21.5104
|
| 2 |
Yu-hong Liu, Xiao-bo Han, Yue-hai Fei, Hong-tao Xu. Long-term low-dose tolvaptan treatment in hospitalized male patients aged >90 years with hyponatremia. Medicine 2017; 96(52) doi: 10.1097/MD.0000000000009539
|
| 3 |
Makoto Segawa, Isao Sakaida. Clinical Investigation of Portal Hypertension. 2019; doi: 10.1007/978-981-10-7425-7_51
|
| 4 |
Ramesh Kumar, Rajeev Nayan Priyadarshi, Utpal Anand. Chronic renal dysfunction in cirrhosis: A new frontier in hepatology. World Journal of Gastroenterology 2021; 27(11): 990-1005 doi: 10.3748/wjg.v27.i11.990
|
| 5 |
Amruta Tripathy, Rituparna Maiti, Monalisa Jena, Archana Mishra, Anand Srinivasan. Effect of alpha agonists on the prevention of postparacentesis circulatory dysfunction in patients with refractory or recurrent ascites: a meta-analysis. European Journal of Gastroenterology & Hepatology 2020; 32(3) doi: 10.1097/MEG.0000000000001594
|
| 6 |
Brett Fortune, Andres Cardenas. Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterology Report 2017; 5(2) doi: 10.1093/gastro/gox010
|
| 7 |
Nitish Rai, Baljinder Singh, Akash Singh, Rajesh Vijayvergiya, Navneet Sharma, Ashish Bhalla, Virendra Singh. Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. Liver International 2017; 37(3) doi: 10.1111/liv.13250
|
| 8 |
Hiroshi Fukui. Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?. World Journal of Gastroenterology 2015; 21(41): 11584-11596 doi: 10.3748/wjg.v21.i41.11584
|
| 9 |
Anand V. Kulkarni, Atoosa Rabiee, Arpan Mohanty. Management of Portal Hypertension. Journal of Clinical and Experimental Hepatology 2022; 12(4) doi: 10.1016/j.jceh.2022.03.002
|
| 10 |
Ran Wang, Lu Chai, Xiaozhong Guo. Pharmacotherapy for Liver Cirrhosis and Its Complications. 2022; doi: 10.1007/978-981-19-2615-0_11
|
| 11 |
P. Angeli. The first Chinese guidelines on the Management of Ascites and its Related Complications in Cirrhosis: a great goal for a great country. Hepatology International 2019; 13(4) doi: 10.1007/s12072-019-09961-4
|
| 12 |
Hiroyuki Nakanishi, Masayuki Kurosaki, Takanori Hosokawa, Yuka Takahashi, Jun Itakura, Shoko Suzuki, Yutaka Yasui, Nobuharu Tamaki, Natsuko Nakakuki, Hitomi Takada, Mayu Higuchi, Yasuyuki Komiyama, Tsubasa Yoshida, Kenta Takaura, Tsuguru Hayashi, Konomi Kuwabara, Sei Sasaki, Namiki Izumi. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. Journal of Gastroenterology 2016; 51(6) doi: 10.1007/s00535-015-1143-3
|
| 13 |
M.J. Broch Porcar, B. Rodríguez Cubillo, J.M. Domínguez-Roldán, L. Álvarez Rocha, M.Á. Ballesteros Sanz, M. Cervera Montes, M. Chico Fernández, J.H. de Gea García, P. Enríquez Giraudo, A. García de Lorenzo y Mateos, R. Gómez López, R. Guerrero Pavón, F. López Sánchez, J.A. Llompart-Pou, S. Lubillo Montenegro, Z. Molina Collado, P. Ramírez Galleymore, M. Riveiro Vilaboa, A. Sánchez Corral, M.E. Herrera-Gutiérrez. Documento práctico del manejo de la hiponatremia en pacientes críticos. Medicina Intensiva 2019; 43(5) doi: 10.1016/j.medin.2018.12.002
|
| 14 |
Dmitry Victorovich Garbuzenko, Nikolay Olegovich Arefyev. Current approaches to the management of patients with cirrhotic ascites. World Journal of Gastroenterology 2019; 25(28): 3738-3752 doi: 10.3748/wjg.v25.i28.3738
|
| 15 |
Shuzhen Wang, Xin Zhang, Tao Han, Wen Xie, Yonggang Li, Hong Ma, Roman Liebe, Honglei Weng, Hui-Guo Ding. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC Gastroenterology 2018; 18(1) doi: 10.1186/s12876-018-0857-0
|
| 16 |
Yoshitaka Arase, Tatehiro Kagawa, Kota Tsuruya, Hirohiko Sato, Erika Teramura, Kazuya Anzai, Shunji Hirose, Ryuzo Deguchi, Koichi Shiraishi, Tetsuya Mine. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites. Clinical Drug Investigation 2019; 39(1) doi: 10.1007/s40261-018-0714-5
|
| 17 |
M.J. Broch Porcar, B. Rodríguez Cubillo, J.M. Domínguez-Roldán, L. Álvarez Rocha, M.Á. Ballesteros Sanz, M. Cervera Montes, M. Chico Fernández, J.H. de Gea García, P. Enríquez Giraudo, A. García de Lorenzo y Mateos, R. Gómez López, R. Guerrero Pavón, F. López Sánchez, J.A. Llompart-Pou, S. Lubillo Montenegro, Z. Molina Collado, P. Ramírez Galleymore, M. Riveiro Vilaboa, A. Sánchez Corral, M.E. Herrera-Gutiérrez. Practical document on the management of hyponatremia in critically ill patients. Medicina Intensiva (English Edition) 2019; 43(5) doi: 10.1016/j.medine.2019.05.005
|
| 18 |
Ryugen Takahashi, Nobuhisa Akamatsu, Akiko Nakazawa, Rihito Nagata, Akihiko Ichida, Yoshikuni Kawaguchi, Takeaki Ishizawa, Junichi Kaneko, Junichi Arita, Kiyoshi Hasegawa. Effect of the response to preoperative treatment for hepatorenal syndrome on the outcome of recipients of living‐donor liver transplantation. Journal of Hepato-Biliary-Pancreatic Sciences 2022; 29(7) doi: 10.1002/jhbp.1143
|
| 19 |
Salvatore Piano, Marta Tonon, Paolo Angeli. Evidence‐based Gastroenterology and Hepatology 4e. 2019; doi: 10.1002/9781119211419.ch43
|
| 20 |
Y Suzuki, A Naganuma, T Hoshino, T Hatanaka, T Ueno, M Namikawa, D Takizawa, H Arai, H Suzuki, H Takagi, H Tojima, Y Yamazaki, K Sato, S Kakizaki, T Uraoka. Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study. Acta Gastro Enterologica Belgica 2021; 84(1) doi: 10.51821/84.1.357
|
| 21 |
Haruki Uojima, Takeshi Kinbara, Hisashi Hidaka, Ji Hyun Sung, Masachika Ichida, Shinnosuke Tokoro, Sakue Masuda, Satoshi Takizawa, Akiko Sasaki, Kazuya Koizumi, Hideto Egashira, Makoto Kako. Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites. Hepatology Research 2017; 47(3) doi: 10.1111/hepr.12716
|
| 22 |
Hirokazu Chishina, Satoru Hagiwara, Naoshi Nishida, Kazuomi Ueshima, Toshiharu Sakurai, Hiroshi Ida, Yasunori Minami, Masahiro Takita, Masashi Kono, Tomohiro Minami, Mina Iwanishi, Yasuko Umehara, Tomohiro Watanabe, Yoriaki Komeda, Tadaaki Arizumi, Masotoshi Kudo. Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis. Digestive Diseases 2016; 34(6) doi: 10.1159/000448828
|
| 23 |
Xiaoyuan Xu, Zhongping Duan, Huiguo Ding, Wengang Li, Jidong Jia, Lai Wei, Enqiang Linghu, Hui Zhuang. Chinese guidelines on the management of ascites and its related complications in cirrhosis. Hepatology International 2019; 13(1) doi: 10.1007/s12072-018-09923-2
|
| 24 |
Uday Sanglodkar, Mayank Jain, Jayanthi Venkataraman. A Clinical Audit of Diuretic Use in a Cohort of Patients with Decompensated Chronic Liver Disease in South India. Gastroenterology, Hepatology and Endoscopy Practice 2023; 3(1) doi: 10.4103/ghep.ghep_28_22
|
| 25 |
Takamasa Ohki, Koki Sato, Tomoharu Yamada, Mari Yamagami, Daisaku Ito, Koki Kawanishi, Kentaro Kojima, Michiharu Seki, Nobuo Toda, Kazumi Tagawa. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World Journal of Hepatology 2015; 7(12): 1685-1693 doi: 10.4254/wjh.v7.i12.1685
|
| 26 |
HISAMITSU MIYAAKI, YUTAKA NAKAMURA, TATSUKI ICHIKAWA, NAOTA TAURA, SATOSHI MIUMA, HIDETAKA SHIBATA, TAKUYA HONDA, KAZUHIKO NAKAO. Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance. Biomedical Reports 2015; 3(6) doi: 10.3892/br.2015.521
|
| 27 |
Satoru Hagiwara, Naoshi Nishida, Hirokazu Chishina, Hiroshi Ida, Toshiharu Sakurai, Yoriaki Komeda, Masayuki Kitano, Masatoshi Kudo. Cases with Refractory Ascites and a Delayed Response to Tolvaptan. Internal Medicine 2016; 55(22) doi: 10.2169/internalmedicine.55.7035
|
| 28 |
G. A. Ignatenko, T. E. Kugler, G. G. Taradin, I. V. Rakitskaya, A. A. Kaluga. Efficacy and Safety of Ascites Treatment in Liver Cirrhosis. Safety and Risk of Pharmacotherapy 2022; 10(2) doi: 10.30895/2312-7821-2022-10-2-161-175
|
| 29 |
Yasunari Hiramine, Haruki Uojima, Hiroyuki Nakanishi, Akira Hiramatsu, Takuya Iwamoto, Mutsuumi Kimura, Hideto Kawaratani, Shuji Terai, Hitoshi Yoshiji, Hirofumi Uto, Isao Sakaida, Namiki Izumi, Kiwamu Okita, Kazuhiko Koike. Response criteria of tolvaptan for the treatment of hepatic edema. Journal of Gastroenterology 2018; 53(2) doi: 10.1007/s00535-017-1366-6
|
| 30 |
Kazuto Tajiri, Yoshiharu Tokimitsu, Hiroyuki Ito, Yoshinari Atarashi, Kengo Kawai, Masami Minemura, Satoshi Yasumura, Terumi Takahara, Yukihiro Shimizu, Toshiro Sugiyama. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis. Digestive Diseases 2018; 36(4) doi: 10.1159/000489258
|
| 31 |
Anand V. Kulkarni, Jason Lee, K. Rajender Reddy. Terlipressin in the management of adults with hepatorenal syndrome-acute kidney injury (HRS-AKI). Expert Review of Gastroenterology & Hepatology 2023; 17(11) doi: 10.1080/17474124.2023.2273494
|
| 32 |
Xianxian Zhang, Cai’e Wang, Alastair O’Brien, Xingshun Qi. Recent Advances in Liver Cirrhosis Related Complications. 2025; doi: 10.1016/B978-0-443-21938-2.00006-0
|
| 33 |
Yu Wang, Huifen Wang, Jun Cheng, Weijiang Ye, Huiguo Ding, Cunliang Deng, Guiqiang Wang, Haihang Zhu, Chengwei Chen, Guozhong Gong, Dazhi Zhang, Qing Xie, Mobin Wan, Xiong Cai, Jun Li, Qing Mao, Yongping Chen, Junqi Niu, Hao Wang, Yiming Mao, Yuwang Tian, Mingji Xian, Yuanyuan Kong, Hong Ma, Xiaojuan Ou, Jidong Jia. Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial. Hepatology International 2026; doi: 10.1007/s12072-026-11093-5
|
| 34 |
Patricia Huelin, Jose Ignacio Fortea, Javier Crespo, Emilio Fábrega. Ascites - Physiopathology, Treatment, Complications and Prognosis. 2017; doi: 10.5772/intechopen.70384
|